Figure 3.
The window of opportunity for effective ricin antitoxin therapy following the oral exposure of Balb/C mice to ricin. A panel of graphs from a therapeutic window efficacy study in which 2.5 mg·mouse−1 ricin antitoxin F(ab′)2 was administered to mice via the intravenous route (iv) at 1, 3 or 5 h after a ricin challenge of ~1050 µg·mouse−1. (A) Kaplan-Meier survival plot; (B) mean bodyweight changes as a percentage of their own weight at 9 a.m. on day 0; and (C) mean accumulative scores of signs of ricin intoxication (Table S1).